News from us and our partners
Tags
Topics
0 results
CinCor Pharma announces topline data for Phase 2 HALO Trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension
Inventiva announces a new Director of the Board of Directors
Moon Surgical announces appointment of Mark Toland as Independent Board Member
Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator Program
Sofinnova Partners appoints Mats Eklund as Partner and Chief Operating Officer
CinCor Pharma announces publication in the New England Journal of Medicine of Phase 2 BrigHtn data on selective aldosterone synthase inhibitor baxdrostat in treatment-resistant hypertension
Sensorion announces US FDA grants Rare Pediatric Disease Designation to OTOF-GT for the treatment of otoferlin gene-mediated hearing loss
Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints
F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim
Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia
Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners
Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide
Muna Therapeutics awarded $4.9M grant from The Michael J. Fox Foundation for Parkinson's research
Biosyntia raises €17.5 million in Series B follow-on to advance sustainable production of active ingredients
AFYREN inaugurates its first factory, AFYREN NEOXY, a first-of-its-kind biorefinery